Diagnostic potential of circulating cell-free nuclear and mitochondrial DNA for several cancer types and nonmalignant diseases: A study on suspected cancer patients

被引:6
|
作者
Sundquist, Kristina [1 ]
Sundquist, Jan [1 ]
Hedelius, Anna [1 ]
Memon, Ashfaque A. [1 ]
机构
[1] Lund Univ, Ctr Primary Hlth Care Res, Malmo, Sweden
关键词
biomarker; cancer; circulating DNA; diagnostic; mitochondrial DNA; nuclear DNA; PLASMA; ORIGIN;
D O I
10.1002/mc.23261
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Circulating cell-free nuclear DNA (nDNA) has been implicated in individual cancer types with a diagnostic value; however, the role of cell-free mitochondrial DNA (mtDNA) in cancers is controversial. We aimed to investigate and compare the diagnostic potential of both nDNA and mtDNA for multiple cancers and to investigate their ability to distinguish multiple cancers from healthy controls and from nonmalignant diseases. We also investigated the prognostic value of both nDNA and mtDNA. The absolute copy number of circulating DNAs in suspected cancer patients (n = 286) referred to a cancer diagnostic center and healthy controls (n = 109) was quantified by droplet digital polymerase chain reaction. Among the suspected cancer patients, 66 (23%) were diagnosed with various cancers, 193 (67%) with nonmalignant diseases, and 27 (10%) with no active disease. Levels of nDNA were significantly higher in cancers (copies/mu l; mean +/- SD, 21.0 +/- 14.2) as compared with nonmalignant diseases (15.2 +/- 10.0) and controls (9.3 +/- 4.1). In contrast, levels of mtDNA were significantly lower in cancers (copies/mu l; mean +/- SD, 68,557 +/- 66,663) and nonmalignant diseases (60,174 +/- 55,831) as compared with controls (98,714 +/- 77,789). Receiver operating curve analysis showed that nDNA not only could distinguish multiple cancers from controls (area under curve [AUC] = 0.78; 95% confidence interval [CI] = 0.70-0.86) but also from nonmalignant diseases (AUC = 0.68; 95% CI = 0.59-0.76). However, mtDNA could only differentiate cancers from controls (AUC = 0.65; 95% CI = 0.56-0.73). Higher levels of nDNA were also associated with increased mortality in the cancer patients (hazard ratio = 2.3; 95% CI = 1.1-4.7). Circulating cell-free nDNA, but not the mtDNA, could distinguish multiple cancers from nonmalignant diseases and was associated with poor survival of cancer patients.
引用
收藏
页码:1362 / 1370
页数:9
相关论文
共 50 条
  • [21] Changes in circulating cell-free nuclear DNA and mitochondrial DNA of patients with adolescent idiopathic scoliosis
    Jiong Li
    Longjie Wang
    Guanteng Yang
    Yunjia Wang
    Chaofeng Guo
    Shaohua Liu
    Qile Gao
    Hongqi Zhang
    BMC Musculoskeletal Disorders, 20
  • [22] Circulating cell-free mitochondrial DNA as a novel cancer biomarker: opportunities and challenges
    Yu, Man
    MITOCHONDRIAL DNA, 2012, 23 (05): : 329 - 332
  • [23] 5-Hydroxymethylcytosine signatures in circulating cell-free DNA as potential diagnostic markers for breast cancer
    Aishan, Nadire
    Ju, Siwei
    Zheng, Zhongqiu
    Chen, Yongxia
    Meng, Qingna
    He, Qina
    Zhang, Jiahang
    Lang, Jiaheng
    Xie, Bojian
    Jin, Lidan
    Shen, Jun
    Lu, Yi
    Cai, Yangjun
    Ji, Feiyang
    Cao, Feilin
    Wang, Linbo
    BIOMARKERS IN MEDICINE, 2025,
  • [24] Diagnostic and prognostic potential of circulating cell-free genomic and mitochondrial DNA fragments in clear cell renal cell carcinoma patients
    Lu, Hongbiao
    Busch, Jonas
    Jung, Monika
    Rabenhorst, Silke
    Ralla, Bernhard
    Kilic, Ergin
    Mergemeier, Steffen
    Budach, Nils
    Fendler, Annika
    Jung, Klaus
    CLINICA CHIMICA ACTA, 2016, 452 : 109 - 119
  • [25] Integrity of cell-free plasma DNA in patients with lung cancer and nonmalignant lung disease
    Schmidt, Bernd
    Weickmann, Sabine
    Witt, Christian
    Fleischhacker, Michael
    CIRCULATING NUCLEIC ACIDS IN PLASMA AND SERUM V, 2008, 1137 : 207 - 213
  • [26] Cell-free DNA in blood is a potential diagnostic biomarker of breast cancer
    Gong, Bo
    Xue, Jianxiang
    Yu, Jing
    Li, Haichuan
    Hu, Heyu
    Yen, Hsuehheng
    Hu, Jinyin
    Dong, Qianggang
    Chen, Fuhua
    ONCOLOGY LETTERS, 2012, 3 (04) : 897 - 900
  • [27] Circulating cell-free DNA variables as marker of ovarian cancer patients: A pilot study
    Stamenkovic, Srdjan
    Cheng, Jie
    Surowy, Harald
    Burwinkel, Barbara
    Guendert, Melanie
    CANCER BIOMARKERS, 2020, 28 (02) : 159 - 167
  • [28] Circulating cell-free DNA in plasma of colorectal cancer patients - A potential biomarker for tumor burden
    Bhangu, Jagdeep Singh
    Taghizadeh, Hossein
    Braunschmid, Tamara
    Bachleitner-Hofmann, Thomas
    Mannhalter, Christine
    SURGICAL ONCOLOGY-OXFORD, 2017, 26 (04): : 395 - 401
  • [29] Cell-free circulating tumor DNA monitoring in pancreatic cancer patients
    Balendran-Braun, S.
    Kieler, M.
    Liebmann-Reindl, S.
    Prager, G. W.
    Streubel, B.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 455 - 455
  • [30] Characterization of cell-free circulating DNA in plasma in patients with prostate cancer
    Delgado, Pamela Oliveira
    Alves, Beatriz Costa A.
    Gehrke, Flavia de Sousa
    Kuniyoshi, Renata Kelly
    Wroclavski, Marcelo Langer
    Del Giglio, Auro
    Affonso Fonseca, Fernando Luiz
    TUMOR BIOLOGY, 2013, 34 (02) : 983 - 986